Last week I went to a breakfast briefing hosted by multinational bank ING, where Stephen Farrell, Global Lead for Pharma & Healthcare, and Diederik Stadig, Healthcare and Technology Economist, talked about where the pharma industry might be heading in 2026.
Their view was simple: if 2025 was about disruption, 2026 will be when the real effects of Trump’s policies start to show.



